FDA-3356-new version 10-24-2007

See Instructions for OMB Statement.

1. REGISTRATION NUMBER
(Field Establishment Identifier)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

ESTABLISHMENT REGISTRATION AND LISTING FOR HUMAN CELLS, TISSUES,
AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps)

FEI

(See reverse side for instructions)

b. DEVICE FDA 2891

NO.

c. DRUG FDA 2656

NO.

b.

ANNUAL REGISTRATION / LISTING

c.

CHANGE IN INFORMATION

d.

INACTIVE

Establishment Functions
Types of HCT / Ps

Recover

Screen

Test

Package

Process

Store

Label

Distribute

13. HCT / Ps REGULATED AS DRUGS
OR BIOLOGICAL
DRUGS

10. ESTABLISHMENT FUNCTIONS AND TYPES OF HCT / Ps

INITIAL REGISTRATION / LISTING

12. HCT / Ps
REGULATED
AS MEDICAL
DEVICES

PART II – HCT / P INFORMATION

3. OTHER FDA REGISTRATIONS
NO.

VALIDATION – FOR FDA USE ONLY

a.

11. HCT / Ps
DESCRIBED IN
21 CFR 1271.10

PART I – ESTABLISHMENT INFORMATION
a. BLOOD FDA 2830

FORM APPROVED: OMB No. 0910-0543. Expiration Date: 8/31/10

2. REASON FOR SUBMISSION

14. PROPRIETARY
NAMES

No HCT/P Specified

4. PHYSICAL LOCATION (Include legal name, number and street, city, state,
country, and post office code.)

a. Bone
b. Cartilage
c. Cornea
d. Dura Mater
a. PHONE:
b.

SATELLITE RECOVERY ESTABLISHMENT
(MANUFACTURING ESTABLISHMENT FEI NO.

c.

TESTING FOR MICRO-ORGANISMS ONLY

e. Embryo
)

5. ENTER CORRECTIONS TO ITEM 4

SIP
Directed
Anonymous

f. Fascia

F

g. Heart Valve
h. Ligament
i. Oocyte

6. MAILING ADDRESS OF REPORTING OFFICIAL (Include institution name if
applicable, number and street, city, state, country, and post office code.)

SIP
Directed
Anonymous

OO
R
P

j. Pericardium
k. Peripheral
Blood Stem
Cells

Autologous
Family Related
Allogeneic

l. Sclera
m. Semen

a. PHONE:
7. ENTER CORRECTIONS TO ITEM 6

SIP
Directed
Anonymous

n. Skin
o. Somatic
Cells

8. U.S. AGENT

p. Tendon

a. E-MAIL ADDRESS:

q. Umbilical
Cord Blood
Stem Cells

Autologous
Family Related
Allogeneic

Autologous
Family Related
Allogeneic

b. PHONE:
r. Vascular Graft
9. REPORTING OFFICIAL’S SIGNATURE
s.
a. TYPED NAME:

t.

b. E-MAIL ADDRESS:

u.

c. TITLE:

FORM FDA 3356 (X/07)

d. DATE:

v.
PSC Graphics (301) 443-1090

EF

Page 1 of 2

INSTRUCTIONS FOR COMPLETING FORM 3356: ESTABLISHMENT REGISTRATION AND LISTING FOR
HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps)
Completion of Form FDA 3356 is required under 21 CFR Part 1271, 207.20 and 807.20 for all establishments engaged in the recovery, processing, storage, labeling, packaging, or distribution of any
HCT/P, or the screening or testing of a cell or tissue donor. After we receive your form, we will update
our records and send a validated form to the reporting official.

Item 9. REPORTING OFFICIAL’S SIGNATURE – The reporting official as listed in Item 6 is the
person appointed by the owner or operator to register the firm and answer all the correspondence
and inquiries relative thereto. The dated signature by the reporting official affirms that all information
contained on the form is true and accurate, to the best of his or her knowledge.

PART I.

PART II. HCT/P INFORMATION (If item 2.c is checked, only indicate the information being
changed)

ESTABLISHMENT INFORMATION

NOTE: You are required to register and list your HCT/Ps by submitting this form if you recover, process, store, label, package, or distribute any HCT/P, or screen or test the HCT/P donor unless one of
the following exceptions applies. You are not required to submit this form if:
a. You use HCT/Ps solely for nonclinical scientific or educational purposes,
b. You remove and then implant HCT/Ps solely for autologous use during the same surgical
procedure,
c. You are a carrier who accepts, receives, carries, or delivers HCT/Ps in the usual course of business as a carrier,
d. You only receive or store HCT/Ps solely for implantation, transplantation, infusion, or transfer
within your facility,
e. You only recover reproductive cells or tissue and immediately transfer them into a sexually intimate partner of the cell or tissue donor, or
f. You are an individual person who works under contract, agreement, or other arrangement
with or for a registered establishment and only recover and send HCT/Ps to the registered
establishment.

Item 10. ESTABLISHMENT FUNCTIONS AND TYPES OF HCT/Ps – Indicate (with an X) the
activity(ies) performed by the registered establishment in conjunction with the type of HCT/P that
the registered establishment manufactures. Test and screen refer to the donor, not the HCT/P. Donor testing establishments that do not know what HCT/P has been recovered from the donor should
indicate (with an X) the test function on the first line – “No HCT/P Specified.” For reproductive
HCT/Ps, indicate whether the HCT/Ps are from sexually intimate partners (SIP), directed, or anonymous. For hematopoietic stem/progenitor cells and somatic cells, indicate whether the HCT/Ps are
autologous, family related, or allogeneic. Family related means allogeneic use in a first degree or
second degree relative.
Item 11. LISTING FOR HCT/Ps DESCRIBED IN 21 CFR 1271.10 – To list HCT/Ps that are described
in 21 CFR 1271.10 (a) indicate (with an X) each HCT/P that fulfills all of the following criteria:
a. The HCT/P is minimally manipulated,
b. The
T HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or
other indications of the manufacturer’s objective intent,
ot
oth

F

OO
R
P

Item 3. OTHER FDA REGISTRATIONS – Provide the registration number if your establishment
ment is
already registered with FDA as a Blood, Medical Device or Drug establishment. Your establishment
will
nt wil
not be given a new registration number and you are not required to fill in items 4 to 8 of Part I. Item 9
must be filled out and signed on all forms. If you choose not to complete, Items 4 to 8 of Part I, you still
must complete and sign Item 9. Then proceed to Part II and provide product information.
Item 4. PHYSICAL LOCATION – Provide the legal name, street address including the postal code
of the actual location and
a. Telephone number.
b. Indicate (with an X) if you are a satellite recovery establishment that supports recovery personnel
in the field by storing supplies or equipment and/or provide temporary storage for recovered HCT/
Ps for shipment to your parent manufacturing establishment, but do not perform any other activities or manufacturing steps. Provide the FEI NO. of your parent manufacturing establishment.

c. Indicate (with an X) if you are an establishment that performs testing of HCT/Ps for micro-organisms if that is the only HCT/P processing function that you perform.
Item 6. MAILING ADDRESS OF THE REPORTING OFFICIAL – Provide the reporting official’s mailing address including the postal code if it is different from the actual location of the
establishment.
Items 8. U.S. AGENT – Non-U.S. establishments only; Provide your U.S. agent name, institution
name if applicable, street address, e-mail address, and telephone number. United States agent means
a person residing or maintaining a place of business in the United States whom a foreign establishment designates as its agent.

After completion, return the form to:
Food and Drug Administration
Center for Biologics Evaluation and Research (HFM-775)
1401 Rockville Pike, Rockville, MD 20852-1448
ATTENTION: Tissue Establishment Registration Coordinator
FAX No. (301) 827-2844
FORM FDA 3356 (X/07)

c.
c The manufacture of the HCT/P does not involve the combination of the cell or tissue component
with a drug or a device, except for a sterilizing, preserving, or storage agent, if the addition of the
agent does not raise new clinical safety concerns with respect to the HCT/P, and either
d. The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity
of living cells for its primary function; or the HCT/P has a systemic effect or is dependent upon
the metabolic activity of living cells for its primary function, and (i) is for autologous use, (ii) is for
allogeneic use in a first-degree or second-degree blood relative, or (iii) is for reproductive use.

If your HCT/P type is not preprinted on the form, list it on lines s-v.
Item 12. HCT/P LISTING FOR MEDICAL DEVICES – Indicate (with an X) each HCT/P that is regulated as a medical device under the Federal Food, Drug, and Cosmetic Act.
Item 13. HCT/P LISTING FOR DRUGS OR BIOLOGICAL DRUGS – Indicate (with an X) each HCT/
P that is regulated as a drug or biological drug under the Federal Food, Drug, and Cosmetic Act and/
or section 351 of the Public Health Service Act.
NOTE: For items 11, 12, and 13 indicate changes to HCT/P listing such as discontinuance (indicate
with a D), or resumption (indicate with an R) of a HCT/P into commercial distribution in June and
December or at the time the change occurs as directed under 21 CFR Part 1271.21. Dates of HCT/P
discontinuance / resumption should be provided on an additional page.
Item 14. PROPRIETARY NAMES – Indicate any applicable proprietary names used for the HCT/Ps
listed, such as a trademark.
NOTE: If necessary add an additional page to complete Items 11, 12, 13, or 14.

Public reporting burden for this collection of information is estimated to average .75 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data
needed, and completing and reviewing the collection of information. Send comments regarding this burden
estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:
Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research (HFM-775)
1401 Rockville Pike, Rockville, MD 20852-1448
ATTENTION: Tissue Establishment Registration Coordinator

An agency may not conduct or sponsor, and
a person is not required to respond to, a
collection of information unless it displays a
currently valid OMB control number.

Page 2 of 2